Nrx Pharmaceuticals, Inc. company information, Employees & Contact Information

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 Yahoo Finance

NRx Pharmaceuticals (NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference NewMediaWire

New Expanded Access Policy for NRX-100 for Suicidal Ideation Psychiatric Times

NRx Pharmaceuticals Announces Expanded Access for NRX-100 Following FDA Fast Track Designation for Suicidal Ideation Treatment Quiver Quantitative

NRx Pharmaceuticals Announces Expanded Access Policy for NRX-100 citybiz

90% Treatment Response Target: NRx Pharma's Revolutionary Mental Health Centers Combine Three Therapies Stock Titan

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference The Manila Times

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer PR Newswire

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics Yahoo Finance

13M Americans Consider Suicide Yearly: NRx's Fast-Tracked Ketamine Treatment Now Available Stock Titan

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine) The Manila Times

13M Patient Market: NRx Pharmaceuticals Secures Major FDA Fast Track Win for Revolutionary Depression Drug Stock Titan

Toxic-Free Ketamine Breakthrough: NRx Pharma Secures Critical FDA Approval for $750M Market Opportunity Stock Titan

NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product Yahoo Finance

Clinical-Stage Biotech NRx Pharmaceuticals Chairman & CEO to Address Global Investment Conference Sept 8 Stock Titan

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics Yahoo Finance

NRx Pharmaceuticals and HOPE Therapeutics to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference | NRXP Stock News Quiver Quantitative

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 Nasdaq

HOPE Therapeutics and NRx Pharmaceuticals Add Cohen & Associates to HOPE Network, Name Dr. Rebecca Cohen Medical Director citybiz

More‑than‑2x TMS effectiveness: NRx to Present Low‑Dose D‑Cycloserine Launch Oct 8, 2025 Stock Titan

New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation Newswire.com

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update Yahoo Finance

NRx Pharmaceuticals Reschedules Q2 Earnings Call, Cites Need for Additional Financial Data Review Stock Titan

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio PR Newswire

NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference Stock Titan

$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) The Globe and Mail

$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) The Globe and Mail

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval PR Newswire

User FinancialContent

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) The Globe and Mail

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) PR Newswire

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development PR Newswire

NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir PR Newswire

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 PR Newswire